List of Excipients in Branded Drug CANDESARTAN CILEXETIL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Par Pharmaceutical Inc	CANDESARTAN CILEXETIL	candesartan cilexetil	49884-658	CARBOXYMETHYLCELLULOSE CALCIUM
Par Pharmaceutical Inc	CANDESARTAN CILEXETIL	candesartan cilexetil	49884-658	FERRIC OXIDE RED
Par Pharmaceutical Inc	CANDESARTAN CILEXETIL	candesartan cilexetil	49884-658	HYDROXYPROPYL CELLULOSE

Generic Drugs Containing CANDESARTAN CILEXETIL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	candesartan cilexetil	0378-3224	CARBOXYMETHYLCELLULOSE CALCIUM
Mylan Pharmaceuticals Inc	candesartan cilexetil	0378-3224	GLYCERYL MONOSTEARATE
Mylan Pharmaceuticals Inc	candesartan cilexetil	0378-3224	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in CANDESARTAN CILEXETIL?

# Of NDCs	Excipient
11	CARBOXYMETHYLCELLULOSE CALCIUM
8	FERRIC OXIDE RED
2	GLYCERYL MONOSTEARATE

Candesartan Cilexetil Excipient Strategy and Commercial Opportunities

Last updated: October 5, 2026

Candesartan cilexetil is an established generic angiotensin II receptor blocker with limited conventional patent protection and substantial formulation opportunity. Its main development challenge is poor aqueous solubility and variable dissolution. The strongest commercial opportunities are low-cost bioequivalent tablets, orally disintegrating tablets, pediatric liquids, fixed-dose combinations, and differentiated formulations that improve dissolution without creating avoidable regulatory or stability risk.

What excipient problems must a candesartan cilexetil formulation solve?

Candesartan cilexetil is a lipophilic prodrug converted during absorption to candesartan, the active angiotensin II receptor antagonist. The drug has low aqueous solubility, making dissolution a potential limiting factor for oral exposure. Formulation performance depends on particle size, wetting, disintegration, granulation method, compression force, and excipient compatibility.

The principal formulation risks are:

Risk	Commercial consequence	Excipient response
Low aqueous solubility	Slow or incomplete dissolution	Wetting agents, particle-size reduction, amorphous dispersion, lipid systems
Hydrophobic drug particles	Poor tablet wetting	Surfactants, hydrophilic binders, porous carriers
Excessive compression	Delayed disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate
Hydrolysis or chemical degradation	Reduced assay and shelf life	Low-moisture excipients, protective packaging, controlled granulation
Blend segregation at low drug load	Content-uniformity failure	Ordered mixing, granulation, particle engineering
Taste and swallowability issues	Poor pediatric or geriatric adherence	Flavors, sweeteners, taste masking, orally disintegrating systems

The reference Atacand tablet contains inactive ingredients including carboxymethylcellulose calcium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and corn starch. Product-specific excipient compositions vary among approved generic products. The FDA-approved labeling identifies candesartan cilexetil tablets in 4 mg, 8 mg, 16 mg, and 32 mg strengths, with an additional hydrochlorothiazide combination product marketed as Atacand HCT. [1]

Which excipients are most suitable for candesartan cilexetil tablets?

A conventional immediate-release tablet remains the lowest-risk commercial platform. The preferred excipient strategy should improve wetting and disintegration while preserving a simple ANDA development path.

Direct-compression platform

A direct-compression formula can use:

• Microcrystalline cellulose as a dry binder and compression aid
• Croscarmellose sodium or crospovidone as the primary superdisintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate at controlled concentration as lubricant
• Lactose monohydrate or mannitol as a diluent
• Sodium lauryl sulfate or poloxamer at low concentration as a wetting agent

A practical starting design would use microcrystalline cellulose and mannitol or lactose for bulk, croscarmellose sodium for rapid breakup, and a low level of surfactant to improve water penetration. Magnesium stearate should be optimized carefully because over-lubrication can create a hydrophobic tablet surface and slow dissolution.

Wet-granulation platform

Wet granulation can improve blend uniformity and tablet robustness, particularly for low-dose 4 mg and 8 mg strengths. Hydroxypropyl cellulose, povidone, or copovidone can function as binders. The process must control water exposure and drying temperature because moisture can affect chemical stability and granule density.

Wet granulation is attractive where the development target includes:

• Better content uniformity
• Reduced segregation
• Higher tablet hardness
• More consistent scale-up
• Lower friability

It is less attractive when the formulation requires the lowest manufacturing cost or when the drug shows sensitivity to aqueous processing.

Lactose-free and sugar-free platforms

Lactose-free products can use mannitol, microcrystalline cellulose, dibasic calcium phosphate, or partially pregelatinized starch. Mannitol is particularly useful for orally disintegrating tablets because it provides a cooling mouthfeel and acceptable taste profile. A lactose-free claim may support pharmacy substitution and procurement opportunities, although it does not by itself create meaningful patent exclusivity.

What formulation approaches can improve candesartan cilexetil dissolution?

The commercial value of a differentiated formulation depends on whether it produces a measurable clinical, regulatory, or adherence benefit. Dissolution improvement alone may not support a new product unless the formulation qualifies for a distinct regulatory pathway or addresses a recognized patient need.

Particle-size reduction

Micronization is the least complex solubility intervention. Smaller particles increase surface area and can improve dissolution if wetting is adequate. The main risks are electrostatic behavior, agglomeration, poor flow, and content-uniformity variation.

A micronized formulation should control:

• D90 and D50 particle-size distribution
• Specific surface area
• Bulk and tapped density
• Agglomeration during blending
• Dissolution across physiologic pH conditions

Particle engineering is generally more compatible with an ANDA than a novel delivery system, provided the finished product meets bioequivalence and quality requirements.

Amorphous solid dispersion

An amorphous solid dispersion using polymers such as copovidone, hydroxypropyl methylcellulose acetate succinate, or polyvinylpyrrolidone can increase apparent solubility. The approach has higher development complexity because physical stability, recrystallization, residual solvent, and moisture uptake must be controlled.

A solid dispersion is most commercially relevant when it delivers one of the following:

• Faster onset of dissolution
• Lower dose burden
• More consistent exposure under variable gastric conditions
• A pediatric or geriatric dosage form
• A 505(b)(2) product with a clinically supportable advantage

For a mature antihypertensive, the cost of proving a meaningful advantage may exceed the value of the formulation unless the product has strong channel access or combination-product economics.

Lipid-based systems and self-emulsifying formulations

Candesartan cilexetil's lipophilic character makes lipid-based delivery technically plausible. Medium-chain triglycerides, long-chain glycerides, surfactants, and cosolvents can improve dispersion in gastrointestinal fluids.

These systems create additional risks:

• Capsule shell compatibility
• Oxidative stability
• Fill-volume limitations
• Leakage or migration
• More complex manufacturing
• Higher cost of goods
• Greater regulatory scrutiny for a modified product

Lipid systems are more commercially defensible in a novel formulation than in a standard generic tablet.

Cyclodextrin and polymeric complexes

Cyclodextrins and hydrophilic polymers may improve apparent solubility and wetting. Their commercial feasibility depends on dose, excipient safety limits, regulatory history, and the amount of complexing agent required. High excipient loading can produce oversized tablets or liquid-dose-volume problems.

What dosage forms offer the strongest commercial opportunity?

Immediate-release tablets

Immediate-release tablets represent the largest and lowest-risk opportunity. The core value proposition is reliable bioequivalence, low manufacturing cost, and supply continuity.

Key development priorities are:

1. Fast and consistent disintegration.
2. Robust dissolution across pH conditions.
3. Low-cost excipient sourcing.
4. Stable 4 mg, 8 mg, 16 mg, and 32 mg strengths.
5. Scalable manufacturing across multiple sites.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with dysphagia, older adults, and patients with adherence challenges. Mannitol, crospovidone, croscarmellose sodium, flavoring systems, and taste-masking technologies are likely candidates.

Candesartan cilexetil has a bitter or unpleasant taste profile that may require polymer coating, ion-exchange resin complexation, cyclodextrin complexation, or flavor masking. The product must maintain rapid disintegration without compromising dose uniformity.

Oral suspension or pediatric liquid

Candesartan is used in pediatric hypertension, and the FDA label provides pediatric dosing information for selected age groups. [1] A ready-to-use suspension or powder for reconstitution could create a practical opportunity where approved commercial liquid options are limited.

A liquid product must address:

• Uniform redispersion
• Sedimentation
• Chemical stability
• Microbial preservation
• Container-closure compatibility
• Dose-measuring accuracy
• Palatability

Suspensions are generally more practical than true solutions because of candesartan cilexetil's poor water solubility. A dry powder for reconstitution can reduce hydrolytic and microbial risk during distribution.

Fixed-dose combinations

The most commercially relevant combination opportunity is candesartan cilexetil with hydrochlorothiazide. Atacand HCT is approved in multiple strength combinations, including 16/12.5 mg and 32/12.5 mg presentations. [2]

Combination products can improve adherence and reduce pill burden. They also increase formulation complexity because the two active ingredients may have different particle properties, dose ratios, and stability profiles. A manufacturing platform should evaluate separate granulation, co-processing, or multilayer-tablet approaches if blend uniformity is difficult.

Potential future combinations with other antihypertensive classes may have clinical logic, but regulatory and commercial value depends on treatment guidelines, prescribing patterns, and the ability to establish a differentiated indication.

What patents protect candesartan cilexetil and when does exclusivity end?

The original candesartan and candesartan cilexetil patent estate originated with Takeda and related inventors. Foundational patent families included European application EP 0 459 136 and U.S. patent families directed to benzimidazole derivatives and their prodrug forms. The principal U.S. compound protection expired years ago, and candesartan cilexetil is now widely marketed as a generic drug.

Protection category	Status
Original compound and prodrug patents	Expired
Original U.S. market exclusivity	Expired
Pediatric exclusivity associated with the original product	Expired
Conventional tablet formulation protection	No meaningful barrier to routine generic development
Method-of-use patents	Any remaining rights would require claim-specific and jurisdiction-specific review
Manufacturing-process patents	Potentially relevant only if still enforceable and technically practiced
Biosimilar exclusivity	Not applicable because candesartan cilexetil is a small molecule

The FDA Orange Book is the controlling source for current listed patents and exclusivity entries for approved U.S. products. [3] A commercial filing strategy should distinguish between expired foundational rights, any live formulation or process claims, and patents listed for specific reference products.

What is the FDA regulatory status of candesartan cilexetil?

Candesartan cilexetil is an FDA-approved small-molecule prescription drug. Generic immediate-release tablets are generally developed through the abbreviated new drug application pathway, with pharmaceutical equivalence and bioequivalence to the relevant reference listed drug.

A differentiated formulation may require a 505(b)(2) application if it departs materially from the reference product and relies partly on FDA findings for safety or efficacy. Examples include:

• New dosage form
• New route of administration
• Modified-release profile
• Novel suspension
• Clinically differentiated delivery technology
• New fixed-dose combination

A routine excipient substitution does not normally create independent market exclusivity. Any commercial advantage must come from approval status, supply reliability, cost, adherence, formulary positioning, or a patentable formulation or manufacturing process.

Are there Paragraph IV challenges or biosimilar risks?

Candesartan cilexetil is not subject to biosimilar competition because it is a chemically synthesized small molecule. Competition occurs through ANDAs and, for differentiated products, potentially through 505(b)(2) applications.

Historical Paragraph IV activity was associated with the entry of generic candesartan products after the original patent estate ceased to block competition. There is no biosimilar pathway or biologic reference-product exclusivity issue.

For a new formulation, the principal legal risks are:

• Orange Book-listed formulation patents
• Method-of-use patents
• Process patents
• Patent infringement claims based on manufacturing steps
• Regulatory exclusivity attached to a 505(b)(2) product
• State substitution and reference-product designation issues

What patent litigation and settlement risks affect the product?

The current commercial risk is low for standard candesartan cilexetil tablets because the core patent estate has expired and multiple generic suppliers exist. Litigation risk increases if a company launches a novel formulation that relies on proprietary particle engineering, amorphous dispersion, taste masking, modified release, or a new combination.

A formulation company should test whether its product:

• Uses a patented polymer or processing method
• Practices a claimed particle-size range
• Uses a protected solid-dispersion ratio
• Copies a patented tablet architecture
• Infringes a method-of-use claim through labeling
• Requires a licensed manufacturing step

Settlement agreements are commercially relevant mainly when a live formulation or method patent remains listed. They are not expected to materially constrain standard immediate-release generic entry based solely on expired compound rights.

How strong is the candesartan cilexetil patent estate?

The estate is weak for ordinary generic tablets and stronger only in narrow, claim-specific formulation areas.

Estate segment	Strength for new entrants
Active ingredient	Low barrier because foundational protection expired
Standard tablet composition	Low to moderate, depending on live claims
Particle engineering	Moderate if claims are narrow and technically practiced
Solid dispersion	Moderate to high if a valid patent covers composition and process
Pediatric suspension	Potentially moderate
Fixed-dose combination	Moderate where formulation or indication claims remain active
Manufacturing process	Highly dependent on claim scope and proof of practice
Trade secrets	Potentially meaningful for scale-up and impurity control

A new entrant should prioritize freedom-to-operate around the formulation process rather than relying only on an ingredient patent search. Process claims can create exposure even when active-ingredient patents are expired.

Which companies are competing in the candesartan cilexetil market?

The U.S. market includes the originator Takeda product and multiple generic manufacturers, depending on strength, dosage form, and supply period. Generic competition has historically involved large multinational suppliers and specialized generic companies. Market share is concentrated by purchasing contracts, wholesaler relationships, manufacturing reliability, and shortage performance rather than by compound patent differentiation.

The most defensible commercial positions are:

• Lowest-cost high-volume tablet supply
• Reliable supply of all four strengths
• Single-source or dual-source contract manufacturing
• Lactose-free or dye-free product
• Pediatric suspension
• Orally disintegrating tablet
• Candesartan/hydrochlorothiazide combination supply
• Geographic expansion into markets with limited local production

What revenue exposure and commercial opportunities exist?

Candesartan cilexetil is a mature, price-competitive product. A standard tablet launch is unlikely to support premium pricing without a supply, formulation, or channel advantage. Revenue exposure is therefore driven by volume, manufacturing cost, customer concentration, and contract duration.

A basic commercial model is:

Revenue = annual units x net price per unit

Gross profit is driven by:

Gross profit = net sales - active pharmaceutical ingredient cost - excipient cost - conversion cost - quality cost - distribution cost - rebates

The highest-probability opportunities are:

1. High-volume ANDA tablets with efficient manufacturing.
2. Combination tablets that reduce pill burden.
3. Pediatric liquid or powder-for-reconstitution products.
4. Orally disintegrating tablets for dysphagia and adherence.
5. Supply agreements in markets with recurring generic shortages.
6. Contract development and manufacturing of low-solubility antihypertensive products.
7. Region-specific products using excipients accepted by local regulators.

How should a company prioritize its candesartan cilexetil excipient program?

A staged strategy limits technical and regulatory risk.

Phase 1: Conventional generic platform

Develop a direct-compression or dry-granulation tablet using microcrystalline cellulose, a superdisintegrant, a suitable diluent, colloidal silicon dioxide, and controlled magnesium stearate. Use micronized active ingredient if needed.

Phase 2: Dissolution-enhanced platform

Evaluate low-level surfactant, particle-size reduction, wet granulation, and hydrophilic carrier systems. Select the lowest-complexity approach that produces robust dissolution and bioequivalence.

Phase 3: Differentiated product

Advance an orally disintegrating tablet, pediatric suspension, or solid-dispersion product only if the target market supports premium pricing, regulatory differentiation, or channel access.

The development program should include comparative dissolution, stability under accelerated and long-term conditions, impurity profiling, excipient compatibility, scale-up robustness, and fed-versus-fasted pharmacokinetic assessment where required.

Key Takeaways

• Candesartan cilexetil is a mature generic small molecule with expired foundational compound protection.
• Poor aqueous solubility is the main excipient and formulation challenge.
• Immediate-release tablets offer the lowest regulatory and manufacturing risk.
• Microcrystalline cellulose, croscarmellose sodium, mannitol or lactose, colloidal silicon dioxide, and controlled magnesium stearate are practical starting excipients.
• Micronization and wetting enhancement are more commercially efficient than complex delivery systems for standard generic products.
• Pediatric liquids, orally disintegrating tablets, and candesartan/hydrochlorothiazide combinations offer the clearest differentiated opportunities.
• Biosimilar risk is not applicable.
• Patent risk is concentrated in narrow formulation, process, combination, and method-of-use claims.
• Commercial success depends more on cost, supply reliability, bioequivalence, and channel access than on active-ingredient exclusivity.

FAQs

Can candesartan cilexetil be formulated as an oral solution?

A true aqueous solution is difficult because of low water solubility. A suspension or powder for reconstitution is generally more practical and can use wetting agents, suspending polymers, buffers, sweeteners, and preservatives.

Which superdisintegrant is best for candesartan cilexetil tablets?

Croscarmellose sodium and crospovidone are strong candidates. The selection should be based on dissolution, tablet hardness, lubricant sensitivity, stability, and scale-up performance.

Is lactose suitable for candesartan cilexetil?

Lactose is suitable when compatibility, patient labeling, and market requirements permit its use. Mannitol, microcrystalline cellulose, and dibasic calcium phosphate support lactose-free alternatives.

Does candesartan cilexetil require a solubility-enhancing formulation?

Not necessarily. A conventional generic tablet can be commercially viable if it meets dissolution and bioequivalence requirements. Solubility enhancement becomes more important for rapid-disintegration, pediatric, orally disintegrating, or clinically differentiated products.

Can an excipient change create patent protection for a candesartan product?

A routine excipient substitution generally does not create meaningful exclusivity. Patent value is more likely to arise from a novel composition, defined particle architecture, solid dispersion, delivery system, manufacturing process, or clinically differentiated dosage form.

References

1. U.S. Food and Drug Administration. (2023). Candesartan cilexetil tablets: Prescribing information. FDA.
2. U.S. Food and Drug Administration. (2023). Atacand HCT: Prescribing information. FDA.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, 45th edition. FDA.